All In Biotech

Drug Trial Radar · NCT07263594

A Study of DB-1324 in Advanced/Metastatic Gastrointestinal Tumors

A Phase 1/2, Multicenter, Open-Label, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1324 in Participants With Advanced/Metastatic Gastrointestinal Tumors

Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

127

Planned (sponsor's estimate)

Start

Jan 20, 2026

Primary completion

Dec 2028

Study completion Dec 2028

Sponsor

Lead sponsor
DualityBio Inc.Industry
Sponsor type
Industry
Collaborators
GlaxoSmithKline
First posted
Dec 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study, the first clinical trial, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of DB-1324.

Conditions

  • Gastrointestinal Cancer

Interventions

  • DB-1324Drug

    Administered I.V.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Escalation and Backfill parts: Percentage of Participants with Dose-Limiting Toxicities (DLTs) as assessed by CTCAE v5.0.Time frame: Up to safety follow-up visit, approximately 30 days post-treatment
  2. Dose Escalation and Backfill parts: Percentage of Participants with Serious Adverse Events (SAEs) as assessed by CTCAE v5.0.Time frame: Up to safety follow-up visit, approximately 30 days post-treatment
  3. Dose Escalation and Backfill parts: Percentage of participants with Treatment Emergent Adverse Events (TEAEs) , Grade ≥ 3 TEAE, TEAE leading to dose reduction/interruption/discontinuationTime frame: Up to safety follow-up visit, approximately 30 days post-treatment
  4. Dose Escalation and Backfill parts: Maximum Tolerated Dose(MTD) of DB-1324Time frame: Up to safety follow-up visit, approximately 30 days post-treatment

Locations

9 sites in 3 countries. Site status is shown where the registry gives one.

  • USA05-0

    Port Saint Lucie, Florida · Recruiting

  • USA02-0

    Grand Rapids, Michigan · Recruiting

  • USA01-0

    Huntersville, North Carolina · Recruiting

  • USA03-0

    Cincinnati, Ohio · Recruiting

  • AUS02-0

    Randwick, New South Wales, Australia · Recruiting

  • AUS03-0

    South Brisbane, Queensland, Australia · Recruiting

  • AUS01-0

    Nedlands, Western Australia, Australia · Recruiting

  • CHN01-0

    Beijing, China · Recruiting

  • CHN04-0

    Beijing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.